(Q36632228)

15 August 2017

1 reference

title

Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs (English)

1 reference

chronic renal insufficiency

15 August 2017

1 reference

1 reference

based on heuristic

inferred from title

secondary hyperparathyroidism

1 reference

based on heuristic

inferred from title

author name string

Angel L M de Francisco

series ordinal

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

16

1 reference

15 August 2017

page(s)

2215-2224

1 reference

Secondary hyperparathyroidism: review of the disease and its treatment.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Calcium receptor and regulation of parathyroid hormone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Identification and functional characterization of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Pathogenesis of refractory secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Parathyroid hormone secretion in vivo. Demonstration of a calcium-independent nonsuppressible component of secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Calcimimetics and calcilytics--fooling the calcium receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Adynamic bone and chronic renal failure: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Progressive accumulation of lanthanum in the liver of normal and uremic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Blast from the past: the aluminum's ghost on the lanthanum salts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Intermittent intravenous followed by intermittent oral 1 alpha(OH)D3 treatment of secondary hyperparathyroidism in uraemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Long-term intravenous calcitriol in secondary hyperparathyroidism: the role of technetium-99m-MIBI scintigraphy in predicting the response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Vitamin D receptor: mechanisms for vitamin D resistance in renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Cinacalcet HCl: a novel therapeutic for hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Calcimimetics with potent and selective activity on the parathyroid calcium receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Achieving therapeutic targets in the treatment of secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2215

10.1517/14656566.7.16.2215

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference